<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04264962</url>
  </required_header>
  <id_info>
    <org_study_id>BeijingDHYZY</org_study_id>
    <nct_id>NCT04264962</nct_id>
  </id_info>
  <brief_title>Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter</brief_title>
  <acronym>YYFZJDTRHCLT3D</acronym>
  <official_title>Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xiyuan Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Ditan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical research of Yang Yin Fu Zheng Jie Du therapy in recurrence of Hepatocellular
      Carcinoma less than 3 cm in diameter.The purpose of this study is to observe the efficacy of
      routine medical care combined with Yang Yin Fu Zheng Jie Du therapy in 1 year recurrence for
      patients belong to Hepatocellular Carcinoma less than 3 cm in diameter.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrance rate</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life (QOL) questionnaire</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Yang Yin Fu Zheng Jie Du therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine medical care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yang Yin Fu Zheng Jie Du therapy</intervention_name>
    <description>Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.</description>
    <arm_group_label>Yang Yin Fu Zheng Jie Du therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Routine medical care</intervention_name>
    <description>Routine medical care</description>
    <arm_group_label>Routine medical care</arm_group_label>
    <arm_group_label>Yang Yin Fu Zheng Jie Du therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet the criteria of hepatocellular carcinoma

          -  Ages Eligible for Study: ≤75 years old;

          -  The size of the main nodule and multi-centricity (single lesion, three nodules ≤3 cm)

          -  After transarterial chemoembolisation (TACE) or radiofrequency ablation (RFA)

          -  Surgery cannot be allowed;

          -  Informed consent from the patient.

        Exclusion Criteria:

          -  Serious problem of heart, lung, or kidney with severe dysfunction;

          -  Pregnant or child breast feeding women;

          -  Mental or cognitive disorders;

          -  Participating in other drug trials;

          -  Who are allergic to the study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhiyun Yang, doctor</last_name>
    <phone>+8613439696988</phone>
    <email>13439696988@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhiyun Yang</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100015</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiyun Yang, doctor</last_name>
      <phone>+8613439696988</phone>
      <email>13439696988@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 9, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Ditan Hospital</investigator_affiliation>
    <investigator_full_name>Zhiyun Yang</investigator_full_name>
    <investigator_title>Archiater, Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

